University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...
Jul 19, 2018
0
65
San Diego startup AltheaDx, which developed a molecular test designed to guide therapy for depression and anxiety based on a patient's genetics, is being acquired for $65 million in stock and cash.
Apr 7, 2022
0
3
Researchers at the Medical University of South Carolina (MUSC) have found a way to target drug-resistant esophageal cancer cells by exploiting the different energy needs of cancerous versus healthy cells. This breakthrough ...
May 21, 2019
0
188
Scientists at the Garvan Institute of Medical Research have identified molecular profiles of the surrounding matrix of a common type of lung cancer that might indicate which patients are likely to develop aggressive tumors.
Nov 20, 2022
1
402
Scientists from an international consortium led by Dr. Eduard Batlle, head of the Colorectal Cancer laboratory at IRB Barcelona, ICREA researcher and group leader of CIBER de Cáncer (CIBERONC), together with the Dutch company ...
Apr 25, 2022
0
68
A UT Southwestern researcher led a team that identified a new vulnerability in kidney tumors, the 10th most common cause of cancer death in men and women.
Jan 17, 2020
0
160
All cells need nutrients, but cancer cells are notoriously power hungry. As a result, cancer cells must alter their metabolism to provide the additional fuel needed for them to survive, grow and spread.
Feb 3, 2016
0
52
DEAR MAYO CLINIC: My brother was diagnosed with stage 0 squamous cell carcinoma in situ in one of his vocal cords. He has been through several endoscopic surgeries, but the carcinoma keeps coming back. His doctors do not ...
May 22, 2019
0
0
(HealthDay)—Libtayo (cemiplimab-rwlc) injection has been approved by the U.S. Food and Drug Administration to treat advanced squamous cell carcinoma (CSCC), the agency said in a news release.
Oct 1, 2018
0
1
(AP) -- The Food and Drug Administration has approved a new Pfizer drug for patients with advanced kidney cancer that has spread to other parts of the body despite treatment with at least one previous drug.
Jan 27, 2012
0
0
